| http://www.w3.org/ns/prov#value | - SCCs do not commonly harbor somatic oncogene-activating mutations, but instead are associated with frequent mutational inactivation of tumor suppressor pathways including p53 and NOTCH, the therapeutic implications of which remain to be established (2, 3).
|
